Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Washington University School of Medicine- Sherman Cancer Center
mi
from
Saint Louis, MO
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Washington University School of Medicine- Sherman Cancer Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
St. Vincents Comprehensive Cancer Center
mi
from
New York, NY
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
St. Vincents Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
New York-Presbyterian Hospital
mi
from
New York, NY
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
New York-Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
SUNY Upstate Medical University
mi
from
Syracuse, NY
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
MBCCOP Our Lady of Mercy Cancer Center New York Medical College
mi
from
The Bronx, NY
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
MBCCOP Our Lady of Mercy Cancer Center New York Medical College
mi
from
The Bronx, NY
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Duke Univ Med Ctr
mi
from
Durham, NC
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Cleveland Clinic Myeloma Program
mi
from
Cleveland, OH
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Cleveland Clinic Myeloma Program
mi
from
Cleveland, OH
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Ohio State University
mi
from
Columbus, OH
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Kaiser Permanente Northwest Region Center for Health Research
mi
from
Portland, OR
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Kaiser Permanente Northwest Region Center for Health Research
mi
from
Portland, OR
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Charleston Hematology Oncology, PA
mi
from
Charleston, SC
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Charleston Hematology Oncology, PA
mi
from
Charleston, SC
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Medical University of SC
mi
from
Charleston, SC
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Medical University of SC
mi
from
Charleston, SC
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
South Carolina Oncology Group
mi
from
West Columbia, SC
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
South Carolina Oncology Group
mi
from
West Columbia, SC
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Sarah Cannon Cancer Center
mi
from
Nashville, TN
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Froedtert Hospital/BMT Medical College of Wisconsin
mi
from
Milwaukee, WI
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Froedtert Hospital/BMT Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/18/2017
Cross Cancer Institute
mi
from
Edmonton,
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/18/2017
Cross Cancer Institute
mi
from
Edmonton,
Click here to add this to my saved trials
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
A Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients
Status: Enrolling
Updated:  9/19/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
A Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients
Status: Enrolling
Updated: 9/19/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Active Immunization of Sibling Stem Cell Transplant Donors Against Purified Myeloma Protein of the Stem Cell Recipient With Multiple Myeloma in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
Status: Enrolling
Updated:  9/19/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Active Immunization of Sibling Stem Cell Transplant Donors Against Purified Myeloma Protein of the Stem Cell Recipient With Multiple Myeloma in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
Status: Enrolling
Updated: 9/19/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Study of Azacitidine in Combination With MEC (Mitoxantrone, Etoposide, Cytarabine) in Relapsed and Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  9/20/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Study of Azacitidine in Combination With MEC (Mitoxantrone, Etoposide, Cytarabine) in Relapsed and Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 9/20/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated:  9/20/2017
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated: 9/20/2017
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated:  9/20/2017
University of Kansas Cancer Center and Medical Pavilion
mi
from
Westwood, KA
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated: 9/20/2017
University of Kansas Cancer Center and Medical Pavilion
mi
from
Westwood, KA
Click here to add this to my saved trials
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated:  9/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated: 9/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated:  9/20/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated: 9/20/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated:  9/20/2017
Duke Cancer Center
mi
from
Durham, NC
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated: 9/20/2017
Duke Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated:  9/20/2017
Ohio State University
mi
from
Columbus, OH
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated: 9/20/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated:  9/20/2017
Oregon Health and Science University
mi
from
Portland, OR
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated: 9/20/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated:  9/20/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated: 9/20/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated:  9/20/2017
Hackensack University Medical Center - John Theurer Cancer Center
mi
from
Hackensack, NJ
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated: 9/20/2017
Hackensack University Medical Center - John Theurer Cancer Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated:  9/20/2017
Huntsman Cancer Center, University of Utah
mi
from
Salt Lake City, UT
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated: 9/20/2017
Huntsman Cancer Center, University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated:  9/20/2017
Centre Hospitalier Universitaire de Grenoble
mi
from
La Tronche,
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease
Status: Enrolling
Updated: 9/20/2017
Centre Hospitalier Universitaire de Grenoble
mi
from
La Tronche,
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Children's Hospital of Alabama
mi
from
Birmingham, AL
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Southern California Permanente Medical Group
mi
from
Downey, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Southern California Permanente Medical Group
mi
from
Downey, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Children's Hospital Central California
mi
from
Madera, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Children's Hospital Central California
mi
from
Madera, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Children's Hospital of Orange County
mi
from
Orange, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Connecticut Children's Medical Center
mi
from
Hartford, CT
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated:  9/21/2017
Yale University
mi
from
New Haven, CT
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
Status: Enrolling
Updated: 9/21/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials